Saltar al contenido
MilliporeSigma

Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.

Molecular cell (2020-06-07)
Marco Mineo, Shawn M Lyons, Mykola Zdioruk, Niklas von Spreckelsen, Ruben Ferrer-Luna, Hirotaka Ito, Quazim A Alayo, Prakash Kharel, Alexandra Giantini Larsen, William Y Fan, Sophia Auduong, Korneel Grauwet, Carmela Passaro, Jasneet K Khalsa, Khalid Shah, David A Reardon, Keith L Ligon, Rameen Beroukhim, Hiroshi Nakashima, Pavel Ivanov, Paul J Anderson, Sean E Lawler, E Antonio Chiocca
RESUMEN

Tumor interferon (IFN) signaling promotes PD-L1 expression to suppress T cell-mediated immunosurveillance. We identify the IFN-stimulated non-coding RNA 1 (INCR1) as a long noncoding RNA (lncRNA) transcribed from the PD-L1 locus and show that INCR1 controls IFNγ signaling in multiple tumor types. Silencing INCR1 decreases the expression of PD-L1, JAK2, and several other IFNγ-stimulated genes. INCR1 knockdown sensitizes tumor cells to cytotoxic T cell-mediated killing, improving CAR T cell therapy. We discover that PD-L1 and JAK2 transcripts are negatively regulated by binding to HNRNPH1, a nuclear ribonucleoprotein. The primary transcript of INCR1 binds HNRNPH1 to block its inhibitory effects on the neighboring genes PD-L1 and JAK2, enabling their expression. These findings introduce a mechanism of tumor IFNγ signaling regulation mediated by the lncRNA INCR1 and suggest a therapeutic target for cancer immunotherapy.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Rosetta 2(DE3)pLysS Competent Cells - Novagen, Novagen′s Rosetta 2 (pLysS) host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli along with T7 lysozyme activity.
En este momento no podemos mostrarle ni los precios ni la disponibilidad